Travis J Hollmann
Overview
Explore the profile of Travis J Hollmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
4977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Hui Y, Cotzia P, Rana S, Kezlarian B, Lin O, Hollmann T, et al.
J Cutan Pathol
. 2021 Feb;
48(8):1051-1060.
PMID: 33625734
Background: SMARCB1-deficient malignancies can arise in various sites. We describe a novel primary SMARCB1-deficient carcinoma of skin (SDCS) and characterize SMARCB1 mutations in non-melanoma skin cancers (NMSC). Methods: Cases underwent...
32.
Navarrete-Dechent C, Cordova M, Aleissa S, Shoushtari A, Hollmann T, Leitao Jr M, et al.
J Dtsch Dermatol Ges
. 2021 Feb;
19(5):768-770.
PMID: 33569903
No abstract available.
33.
Segal N, Cercek A, Ku G, Wu A, Rimner A, Khalil D, et al.
Clin Cancer Res
. 2021 Jan;
27(8):2200-2208.
PMID: 33504552
Purpose: Immune checkpoint inhibition (ICI) alone is not active in mismatch repair-proficient (MMR-P) metastatic colorectal cancer (mCRC), nor does radiotherapy alone result in objective systemic benefit. However, combined radiotherapy plus...
34.
Li J, Duran M, Dhanota N, Chatila W, Bettigole S, Kwon J, et al.
Cancer Discov
. 2020 Dec;
11(5):1212-1227.
PMID: 33372007
Cytosolic DNA is characteristic of chromosomally unstable metastatic cancer cells, resulting in constitutive activation of the cGAS-STING innate immune pathway. How tumors co-opt inflammatory signaling while evading immune surveillance remains...
35.
Friedman C, Snyder Charen A, Zhou Q, Carducci M, Buckley de Meritens A, Corr B, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33004542
Background: There are limited treatment options for patients with metastatic or recurrent cervical cancer. Platinum-based chemotherapy plus the anti-vascular endothelial growth factor antibody bevacizumab remains the mainstay of advanced treatment....
36.
Zamarin D, Walderich S, Holland A, Zhou Q, Iasonos A, Torrisi J, et al.
J Immunother Cancer
. 2020 Jun;
8(1).
PMID: 32503949
Background: Immune checkpoint inhibitors (ICIs) to date have demonstrated limited activity in advanced ovarian cancer (OC). Folate receptor alpha (FRα) is overexpressed in the majority of OCs and presents an...
37.
Taube J, Akturk G, Angelo M, Engle E, Gnjatic S, Greenbaum S, et al.
J Immunother Cancer
. 2020 May;
8(1).
PMID: 32414858
Objectives: The interaction between the immune system and tumor cells is an important feature for the prognosis and treatment of cancer. Multiplex immunohistochemistry (mIHC) and multiplex immunofluorescence (mIF) analyses are...
38.
Pourmaleki M, Young J, Socci N, Chiang S, Edelweiss M, Li Y, et al.
Oncotarget
. 2019 Nov;
10(58):6152-6167.
PMID: 31692889
Extramammary Paget disease (EMPD) is a rare cutaneous adenocarcinoma of the anogenital region most commonly treated with surgical excision. Surgical margin clearance is often problematic and recurrence rates remain high...
39.
Lezcano C, Pulitzer M, Moy A, Hollmann T, Jungbluth A, Busam K
Am J Surg Pathol
. 2019 Oct;
44(4):503-508.
PMID: 31633488
The distinction of metastatic melanoma from melanocytic nevi in lymph nodes can on occasion be difficult. As diffuse immunohistochemical (IHC) PRAME (PReferentially expressed Antigen in MElanoma) expression is detected in...
40.
Huang Y, Hu J, Chen F, Lecomte N, Basnet H, David C, et al.
Cancer Discov
. 2019 Oct;
10(1):142-157.
PMID: 31582374
TGFβ is an important tumor suppressor in pancreatic ductal adenocarcinoma (PDA), yet inactivation of TGFβ pathway components occurs in only half of PDA cases. TGFβ cooperates with oncogenic RAS signaling...